Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Pharming Group N.V. ADR (PHAR)

Pharming Group N.V. ADR (PHAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pharming Group Announces Restructuring to Cut Costs and Boost Growth Tipranks - Tue Oct 7, 11:28AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

PHAR : 17.80 (-1.60%)
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug Zacks Investment Research - Fri Aug 29, 10:42AM CDT

Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related...

OTLK : 1.8200 (-0.55%)
KNSA : 42.00 (-1.15%)
CRMD : 12.53 (+2.79%)
PHAR : 17.80 (-1.60%)
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin Zacks Investment Research - Tue Aug 26, 11:30AM CDT

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation.The...

KNSA : 42.00 (-1.15%)
CRMD : 12.53 (+2.79%)
CPRX : 24.35 (-0.41%)
PHAR : 17.80 (-1.60%)
Pharming Group to participate in September investor conferences PR Newswire - Thu Aug 24, 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the...

PHAR : 17.80 (-1.60%)
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan PR Newswire - Wed Aug 9, 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled...

PHAR : 17.80 (-1.60%)
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board PR Newswire - Tue Jul 18, 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

KA : 0.5746 (-30.69%)
XFOR : 4.50 (+1.81%)
PHAR : 17.80 (-1.60%)
APRE : 0.9802 (+3.05%)
Pharming Group to report second quarter and first half 2023 financial results on August 3 PR Newswire - Thu Jul 13, 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter...

PHAR : 17.80 (-1.60%)
Pharming announces sale of priority review voucher PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive...

PHAR : 17.80 (-1.60%)
Pharming Group to attend the following Investor Conferences in June PR Newswire - Thu May 25, 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following...

PHAR : 17.80 (-1.60%)
Pharming Group reports financial results for the first quarter of 2023 PR Newswire - Thu May 11, 2023

FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues...

PHAR : 17.80 (-1.60%)

Barchart Exclusives

The Next Market Collapse Will Be Quiet And That Is Exactly Why Investors Will Miss It Barchart - Sat Dec 27, 3:48PM CST
The next market collapse will start silently beneath the surface, and only investors who watch structure rather than headlines will see it coming Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot